Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Fda Inspections
  6. /
  7. Sudershan Vishwanath, M.D.
FDA Inspection
•Sudershan Vishwanath, M.D.•June 13, 2025

Sudershan Vishwanath, M.D. – FDA Inspection, Jun 13, 2025

Record Details

This FDA Inspection record concerns Sudershan Vishwanath, M.D., with an inspection on June 13, 2025, issued by the Center for Drug Evaluation and Research, covering drugs.

Company
Sudershan Vishwanath, M.D.
Inspection Date
June 13, 2025
Product Type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Courtney N. Long (Company Rep)
View Company Profile

ID · cfa2436d-5878-4f37-ab62-d0eed81d46f3

Inspection Facts

Voluntary Action Indicated (VAI)

Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.

Inspection number
1277610
FDA center
Human Drugs
Project area
Bioresearch Monitoring

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Sudershan Vishwanath, M.D.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.